Clinical Trials Browser

margetuximab × Clear all

NCT04425018 2025-11-18

MARGOT

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast Neoplasms

NCT04082364 2025-06-08

MAHOGANY

Phase 2/3 Completed

82 enrolled 22 charts

Gastrointestinal

Stomach Neoplasms

NCT02492711 2025-03-17

SOPHIA

Phase 3 Completed

624 enrolled 17 charts 1 FDA

Neoplasm Metastasis

NCT02689284 2025-03-17

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Phase 1/2 Completed

95 enrolled 26 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01828021 2025-03-13

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Phase 2 Completed

25 enrolled 8 charts

Breast Neoplasms, Recurrence

NCT01148849 2025-02-26

Safety Study of MGAH22 in HER2-positive Carcinomas

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03133988 2025-02-14

Margetuximab Expanded Access Program

Approved for marketing

HER2-positive Breast Cancer

NCT03219268 2023-12-21

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Phase 1 Completed

BreastGastrointestinalGynecologicHead & NeckOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Hematologic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2 Unknown

Breast Cancer Metastatic

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast Neoplasms